The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 23, 2010

Filed:

Jul. 14, 2005
Applicants:

Lisa Selsam Beavers, Franklin, IN (US);

Serge Louis Boulet, Fishers, IN (US);

Terry Patrick Finn, Geneva, CH;

Robert Alan Gadski, Indianapolis, IN (US);

William Joseph Hornback, Fishers, IN (US);

Cynthia Darshini Jesudason, Indianapolis, IN (US);

Richard Todd Pickard, Noblesville, IN (US);

Freddie Craig Stevens, Indianapolis, IN (US);

Grant Mathews Vaught, Indianapolis, IN (US);

Inventors:

Lisa Selsam Beavers, Franklin, IN (US);

Serge Louis Boulet, Fishers, IN (US);

Terry Patrick Finn, Geneva, CH;

Robert Alan Gadski, Indianapolis, IN (US);

William Joseph Hornback, Fishers, IN (US);

Cynthia Darshini Jesudason, Indianapolis, IN (US);

Richard Todd Pickard, Noblesville, IN (US);

Freddie Craig Stevens, Indianapolis, IN (US);

Grant Mathews Vaught, Indianapolis, IN (US);

Assignee:

Eli Lilly and Company, Indianapolis, IN (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/501 (2006.01); C07D 403/14 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention discloses novel aryl oxazole compounds of Formula I (I), or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing and using such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. Formula I (I) or a pharmaceutically acceptable salt thereof, wherein: m is independenlly at each occurrence 1, 2, or 3, Z independently represents carbon (substituted with hydrogen or the optional substituents indicated herein) or nitrogen, provided that when Z is nitrogen then R6 is not attached to Z; R1 and R2 are independently —(C—C) alkyl (optionally substituted with one to three halogens), or R1 and R2 and the nitrogen to which they are attached form an azetidinyl ring, a pyrrolidinyl ring, or a piperidinyl ring, wherein further the azetidinyl, pyrrolidinyl, or piperidinyl ring so formed may be optionally substituted one to three times with R5; R6 is independently at each occurrence —H, -halogen, or —CH.


Find Patent Forward Citations

Loading…